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deviate more than ~2 mm from the gating window center. 
Log files provided the transponder motion during beam-on in 
the actual gated treatments and in simulated non-gated 
treatments with CBCT-guided patient setup. This motion was 
used to reconstruct the actually delivered CTV dose 
distribution with gating and the would-be dose distribution 
without gating. The minimum dose to 95% of the CTV (D95) 
for each fraction and each course was compared with the 
planned CTV D95. 
 
Results: Fig. A shows the internal tumor motion at a fraction 
with large baseline drift of 3mm (LR), 9mm (CC), and 6mm 
(AP) relative to the pre-treatment CBCT. Fig. B shows the 
same motion with four drift compensating couch adjustments 
applied as marked with red lines. The width of the green 
areas indicates the time of beam delivery. The height 
indicates the allowed positions for beam-on without (Fig. A) 
and with (Fig. B) gating. The course mean geometrical error 
was <1.2mm for all gated treatments, but would have ranged 
from -2.8mm to 1.2mm (LR), from 0.7mm to 7.1mm (CC), 
and from -2.6mm to 0.1mm (AP) without gating due to 
baseline drift. Fig. C shows the CTV D95 reduction relative to 
the planned D95 versus the 3D mean error for each fraction 
and course. The mean reduction in D95 for the 12 fractions 
was 1.1% [range: 0.1-2.1%] with gating and 10.8% [0.9-35%] 
without gating. The mean duty cycle was 59% [54-70%]. 
 
 
 
Conclusion: Respiratory gating based on internal 
electromagnetic monitoring was performed for four liver 
SBRT patients. The gating added robustness to the dose 
delivery and ensured a high CTV dose even in the presence of 
large intrafraction motion. 
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Purpose or Objective: Ablative radiotherapy is rapidly 
emerging as an effective treatment for locally advanced 
pancreatic adenocarcinoma. However, the pancreas 
undergoes erratic and unstable respiratory-induced motion, 
which decreases coverage of the tumor and increases dose to 
the duodenum. The purpose of this study was to develop and 
optimize motion management protocols which allow for safe 
delivery of pancreatic SBRT. 
 
Material and Methods: We analyzed 4DCT and CBCT data 
from 35 patients who received pancreatic SBRT; the majority 
were locally advanced tumors receiving 30 Gy in 5 fractions. 
In total, the data from 175 treated fractions was analyzed. 
For each fraction, the daily trajectory of the tumor was 
reconstructed by calculating a Gaussian probability density 
function using the location of gold fiducial markers in the 
CBCT projections. These trajectories represented over 600 
samples of the position of the tumor during the course of 
CBCT acquisition. Using the calculated trajectories, we 
investigated the dosimetric impact of several respiratory 
motion management strategies, including gating based on 
instantaneous kV imaging of implanted fiducial markers. 
 
Results: 4DCT was a poor predictor of pancreatic motion, as 
the amplitude of daily motion exceeded the predictions of 
pre-treatment 4DCT by an average of 3.5 mm in the SI 
direction. In a Fourier-based analysis, these uncertainties 
were correlated with an increase in low-frequency motion 
(potentially due to peristalsis of the duodenum). Abdominal 
compression increased the consistency of motion and reduced 
the amplitude by 2.7 ± 2.8 mm. On average, respiratory 
gating decreased the apparent motion even further, with 
attainable effective motion amplitudes of 2 mm. However, 
gating based on external surrogates (either phase- or 
amplitude-based) is greatly hindered in some patients by the 
inconsistency of pancreatic motion. In these cases, internal 
gating surrogates are warranted. In a simulated clinical 
scenario, fiducial-based internal gating using a 2 mm SI 
window greatly outperformed conventional gating using 
external surrogates (p<0.001), with a mean target D95 of 
99±2%, 95% CI 93-100% (conventional gating – D95 97±7%, 95% 
CI 68-100%). Additionally, we analyzed the dosimetry of 
motion by convolving the dose distribution with phase-
specific motion information. Using these data, we developed 
a metric that predicts patient-specific consistency, and in a 
simulated adaptive protocol which adjusted margins based on 
this metric, there were significant increases in mean target 
D95 and minimum dose. 
 
Conclusion: Motion management is essential in reducing the 
size of target volumes and minimizing dose/side effects to 
the small bowel. Motion uncertainties and patient-specific 
differences warrant an adaptive approach to respiratory 
management. Our data shows that using real-time kV imaging 
of implanted fiducial markers to adapt the gating protocol 
based on the instantaneous position of the tumor 
outperforms conventional approaches. 
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Purpose or Objective: PROMETHEUS (UTN: U1111-1167-2997) 
is a multicentre clinical trial investigating the feasibility of 
stereotactic radiotherapy (SBRT) as a boost technique for 
